Ivonescimab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Humanized (from hamster) |
| Target | PD-1, VEGF-A |
| Clinical data | |
| Other names | AK112 |
| Pharmacokinetic data | |
| Elimination half-life | 6-7 days |
| Identifiers | |
| CAS Number | |
| PubChem SID | |
| DrugBank | |
| UNII | |
Ivonescimab is a humanized bispecific monoclonal antibody currently being trialed for use against non-small-cell lung cancer. Developed by Akeso, it has been approved in China for the treatment of epidermal growth factor receptor-mutated locally advanced or metastatic non-squamous NSCLC in patients who have progressed past tyrosine kinase inhibitor therapy,[1] and is undergoing clinical trials elsewhere.
Mechanism of action
Ivonescimab prevents tumor proliferation and angiogenesis by inhibiting programmed cell death protein 1 and vascular endothelial growth factor A, respectively.[2]
Research
Ivonescimab so far has only completed trials in Chinese patients,[3] and is currently undergoing phase III trials in the United States for the treatment of non-squamous non-small-cell lung cancer and advanced NSCLC.[4]
Society and culture
The initial success of ivonescimab in trials is compared to already-approved drugs such as Merck & Co.'s Keytruda (pembrolizumab); its success has been described as important for the pharmaceutical industry in China.[5]
See also
References
- ^ "国家药监局批准依沃西单抗注射液上市". 国家药品监督管理局 (National Medical Products Administration) (in Chinese). 24 May 2024. Retrieved 6 March 2025.[dead link]
- ^ Zhong TT, Huang ZL, Pang XH, et al. (November 2023). "1194 Mechanism of action of ivonescimab (AK112/SMT112): a first-in-class tetravalent Fc-silent bispecific antibody with dual blockade of PD-1 and VEGF that promotes cooperative biological effects". Journal for Immunotherapy of Cancer. 11: A1316–A1317. doi:10.1136/jitc-2023-SITC2023.1194.
- ^ Helwick V (25 September 2024). "HARMONi-2: Ivonescimab Outperforms Pembrolizumab as First-Line Treatment in NSCLC". The ASCO Post. Retrieved 1 March 2025.
- ^ Dhillon S (September 2024). "Ivonescimab: First Approval". Drugs. 84 (9): 1135–1142. doi:10.1007/s40265-024-02073-w. PMID 39073550.
- ^ Chang W, Ripley W, Cheung E (25 February 2025). "A little-known Chinese company made a drug that beat the world's biggest-selling medicine". CNN. Retrieved 1 March 2025.
External links
- Clinical trial number NCT05499390 for "AK112 in Advanced Non-Small Cell Lung Cancer" at ClinicalTrials.gov
- Clinical trial number NCT05184712 for "Phase 3 Clinical Study of AK112 for NSCLC Patients" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by adding missing information. |
Content Disclaimer
Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.
- The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
- There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
- It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
- Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
- Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.